No Data
No Data
Solid Biosciences Stock Jumps 11% Post-market on FDA Update
Bullish Larimar Therapeutics Insiders Loaded Up On US$522.0k Of Stock
JMP Securities Maintains Larimar Therapeutics(LRMR.US) With Buy Rating, Maintains Target Price $21
Baird Maintains Larimar Therapeutics(LRMR.US) With Buy Rating, Cuts Target Price to $13
Oppenheimer Maintains Larimar Therapeutics(LRMR.US) With Buy Rating, Maintains Target Price $26
We're Hopeful That Larimar Therapeutics (NASDAQ:LRMR) Will Use Its Cash Wisely